Bydureon Bcise

  • Diabetes

Bydureon Bcise Generic Name & Formulations

General Description

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose.

Pharmacological Class

Glucagon-like peptide-1 (GLP-1) receptor agonist.

How Supplied

Single-dose autoinjectors—4

Generic Availability


Bydureon Bcise Indications


Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.

Limitations of Use

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not for treating type 1 diabetes. Not studied in patients with a history of pancreatitis.

Bydureon Bcise Dosage and Administration

Adults and Children

<10yrs: not established. Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. ≥10yrs: 2mg once every 7 days (weekly). Switching from immed- or another ext-rel exenatide product: discontinue, then start Bydureon BCise.

Bydureon Bcise Contraindications


History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2. History of drug-induced immune-mediated thrombocytopenia from exenatide products.

Bydureon Bcise Boxed Warnings

Boxed Warning

Risk of thyroid C-cell tumors.

Bydureon Bcise Warnings/Precautions


Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Do not share pens between patients. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis, drug-induced thrombocytopenia; discontinue if suspected; do not restart if confirmed. History of anaphylaxis or angioedema with another GLP-1 agonist; monitor closely. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Severe GI disorders, eGFR <45mL/min/1.73m2, ESRD: not recommended. Renal transplantation (monitor). Hepatic or severe renal impairment: not studied. Elderly. Pregnancy. Nursing mothers.

Bydureon Bcise Pharmacokinetics

See Literature

Bydureon Bcise Interactions


Do not mix with insulins; avoid adjacent inj sites. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May delay absorption of oral drugs (eg, acetaminophen). Monitor INR more frequently with warfarin.

Bydureon Bcise Adverse Reactions

Adverse Reactions

Nausea, diarrhea, headache, vomiting, constipation, dyspepsia, inj site reactions (eg, pruritus, nodule); acute kidney injury, hypersensitivity reactions (discontinue if occur), possible antibody formation (glycemic response may be attenuated).

Bydureon Bcise Clinical Trials

See Literature

Bydureon Bcise Note

Not Applicable

Bydureon Bcise Patient Counseling

See Literature